Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Istodax (romidepsin)
i
Other names:
depsipeptide, FK 228, FK228, FR 901228, NSC 630176, NSC 630176D
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(9)
News
Trials
Company:
Astellas, BMS
Drug class:
HDAC inhibitor
Related drugs:
‹
chidamide (23)
vorinostat (19)
panobinostat (15)
entinostat (9)
CUDC-907 (8)
OKI-179 (4)
SB939 (4)
belinostat (2)
CG-781 (2)
MGCD0103 (2)
REC-2282 (1)
4SC-202 (1)
JNJ 26481585 (1)
CUDC-101 (0)
givinostat (0)
resminostat (0)
RG2833 (0)
sulforafan alfadex (0)
CKD-581 (0)
CG-745 (0)
kt-3000 series (0)
kt-3283 (0)
VRx-3996 (0)
MTX110 (0)
SHP-141 (0)
OBP-801 (0)
EDO-S101 (0)
VTR-297 (0)
CXD101 (0)
chidamide (23)
vorinostat (19)
panobinostat (15)
entinostat (9)
CUDC-907 (8)
OKI-179 (4)
SB939 (4)
belinostat (2)
CG-781 (2)
MGCD0103 (2)
REC-2282 (1)
4SC-202 (1)
JNJ 26481585 (1)
CUDC-101 (0)
givinostat (0)
resminostat (0)
RG2833 (0)
sulforafan alfadex (0)
CKD-581 (0)
CG-745 (0)
kt-3000 series (0)
kt-3283 (0)
VRx-3996 (0)
MTX110 (0)
SHP-141 (0)
OBP-801 (0)
EDO-S101 (0)
VTR-297 (0)
CXD101 (0)
›
Associations
(9)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
romidepsin
Sensitive: A2 - Guideline
romidepsin
Sensitive
:
A2
romidepsin
Sensitive: A2 - Guideline
romidepsin
Sensitive
:
A2
ERBB3 overexpression
Triple Negative Breast Cancer
ERBB3 overexpression
Triple Negative Breast Cancer
romidepsin
Sensitive: C3 – Early Trials
romidepsin
Sensitive
:
C3
romidepsin
Sensitive: C3 – Early Trials
romidepsin
Sensitive
:
C3
DNMT3A mutation
Lymphoma
DNMT3A mutation
Lymphoma
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
IDH2 mutation
Lymphoma
IDH2 mutation
Lymphoma
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
TET2 mutation
Lymphoma
TET2 mutation
Lymphoma
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
azacitidine + romidepsin
Sensitive: C3 – Early Trials
azacitidine + romidepsin
Sensitive
:
C3
IDH2 mutation
Glioma
IDH2 mutation
Glioma
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
IDH1 mutation
Glioma
IDH1 mutation
Glioma
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
MDM2 amplification + CDK4 amplification
Liposarcoma
MDM2 amplification + CDK4 amplification
Liposarcoma
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
TP53 deletion
B Acute Lymphoblastic Leukemia
TP53 deletion
B Acute Lymphoblastic Leukemia
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
romidepsin
Sensitive: D – Preclinical
romidepsin
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login